ORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia

by Oryzon Genomics

2 days ago
essential thrombocythemia (ET), Iadademstat

Oryzon Genomics a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadadems...

ORYZON reports financial results and corporate update for quarter ended March 31st, 2026

by Oryzon Genomics

20 days ago
Iadademstat, Vafidemstat, Oryzon

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off

ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026

by Oryzon Genomics

21 days ago
Iadademstat, acute myeloid leukemia (AML), European Hematology Association (EHA)

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-mon...

ORYZON to participate in upcoming events in May and June

by Oryzon Genomics

1 month ago
Iadademstat, acute myeloid leukemia, Oryzon Genomics

Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June

ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

by Oryzon Genomics

2 months ago
LSD1 inhibitor, Vafidemstat, borderline personality disorder (BPD)

Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder

ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax

by Oryzon Genomics

2 months ago
iadademstat, leucemia mieloide aguda (LMA), venetoclax

Oryzon Genomics today announced that the United States Patent and Trademark Office has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon’s potent and s...

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors

by Oryzon Genomics

3 months ago
small cell lung cancer (SCLC), iadademstat, PD-1/PD-L1 inhibitors

Oryzon Genomics today announced that the Mexican Patent Office has issued a decision to grant for its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”...

ORYZON reports financial results and corporate update for quarter ended December 31st, 2025

by Oryzon Genomics

3 months ago
Vafidemstat, Iadademstat, Oryzon Genomics

Investment in R&D reached €12.6 million, representing an increase of 50% (€4.2 million) compared to the €8.4 million invested in the previous financial year.

ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadademstat in essential thrombocythemia

by Oryzon Genomics

3 months ago
iadademstat, essential thrombocythemia (ET), Inhibition of LSD1

Oryzon Genomics ha anunciado hoy que la Agencia Europea del Medicamento ha aprobado su Solicitud de Autorización de Ensayo Clínico para iniciar un ensayo clínico de Fase II de iadademstat, el inhi...

ORYZON to participate in upcoming events in February and March

by Oryzon Genomics

3 months ago
Oryzon Genomics, Bio-Neuroscience 2026, SmallCap Event 20th Edition, BIO-Europe Spring 2026, LSX World Congress Europe

Oryzon Genomics, a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events

ORYZON announces appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

by Oryzon Genomics

4 months ago
Dr. Rolando Gutiérrez-Esteinou

Oryzon Genomics, a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Program...

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer

by Oryzon Genomics

4 months ago
iadademstat, LSD1 inhibitor, extensive stage small cell lung cancer (ES-SCLC), atezolizumab

Oryzon Genomics announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and selective LSD1 inhibitor, i...